Alnylam Pharmaceuticals (United States)
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for Alnylam Pharmaceuticals (United States), United States, covering academic research published from 2003 to 2022. Read More.
Open Access Percentage
65%
Total
Publications
659
Total Open
Publications
429
Total
Citations
59K
Open Access
Percentage
65%
Total
Publications
659
Total Open
Publications
429
Total
Citations
59K
Breakdown
Publisher Open
16%
Both
36%
Other Platform Open
13%
Closed
35%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 31%
106
Hybrid 31%
106
No Guarantees 38%
133
Other Platform Open
Domain 84%
269
Institution 27%
87
Other Internet 12%
38
Preprint 11%
36
Public 8%
26
Other Platform Locations
Name | Platform Type | Publications |
|---|---|---|
PubMed Central | Domain | 266 |
Europe PMC | Domain | 208 |
Massachusetts Institute of Technology - DSpace@MIT | Institution | 26 |
Semantic Scholar | Public | 20 |
bioRxiv | Preprint | 20 |
University College London - UCL Discovery | Institution | 14 |
DOI | Other Internet | 14 |
Harvard University - Digital Access to Scholarship at Harvard (DASH) | Institution | 13 |
medRxiv | Preprint | 10 |
Figshare | Public | 10 |